Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
Gilead's recent data from two Phase 3 trials show higher adverse events and lower transplant rates in patients treated with magrolimab.
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies
Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis and primary sclerosing cholangitis. Significant improvements in pruritus and fatigue were observed.
Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?
Mustang Bio shares soar 190.9% on high trading volume as Phase 1/2 trial data for CAR T-cell therapy MB-106 shows positive results.
Marinus Pharmaceuticals Shares Mixed Results From IV Formulated Ganaxolone In Pretreated Seizure Patients
Marinus Pharmaceuticals announces Phase 3 RAISE trial results for IV ganaxolone in refractory status epilepticus.
Philips Zenition 90 Motorized Receives FDA 510(k) Clearance To Help Clinicians Deliver High Quality Care With A High-Powered And Fast Motorized Mobile C-Arm
Intuitive motorization for greater control and high-power (25 kW [1]) for state-of-the-art image quality supports complex vascular needs and a full range of clinical proceduresAutomated workflows contribute to greater
What’s Going On With Ovid Therapeutics After Takeda’s Two Phase 3 Epilepsy Studies Fail?
Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug.
Japan Pharma Giant Takeda’s Anti-Seizure Treatment Flunks In Two Late-Stage Studies
Takeda Pharmaceutical released topline data from its Phase 3 studies, SKYLINE and SKYWAY, on Soticlestat for refractory Dravet and Lennox-Gastaut syndromes
Evoke Pharma Reports Commercial Strategy Progress & Momentum For GIMOTI; Announced The Promotion Of Mark Kowieski To The Role Of Chief Financial Officer In May 2024
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024Promoted former VP of Finance, Mark Kowieski to Chief Financial OfficerSOLANA BEACH, Calif., June 17, 2024
Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative To Improve Quality Of Care Through Identification, Dissemination, And Implementation Of Best Practices For The Diagnosis And Management Of Recur…
– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to work with champions at 15 healthcare sites to implement initiative activities and
BioMarin Presents Data Highlighting Impact Of VOXZOGO In Bone Health And Health-Related Quality Of Life In Achondroplasia At 2024 ICCBH
New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of Observation in Children with AchondroplasiaPhase 2 and 3 Data on VOXZOGO Demonstrate Safety,